# IMPROVE-IT: Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin) vs Simvastatin (P04103)

> **NCT00202878** · PHASE3 · COMPLETED · sponsor: **Organon and Co** · enrollment: 18144 (actual)

## Conditions studied

- Hypercholesterolemia
- Myocardial Infarction

## Interventions

- **DRUG:** ezetimibe/simvastatin
- **DRUG:** simvastatin
- **DRUG:** Placebo for simvastatin 40 mg
- **DRUG:** Placebo for ezetimibe 10 mg/simvastatin 40 mg combination

## Key facts

- **NCT ID:** NCT00202878
- **Lead sponsor:** Organon and Co
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10-17
- **Primary completion:** 2014-09-18
- **Final completion:** 2014-09-18
- **Target enrollment:** 18144 (ACTUAL)
- **Last updated:** 2024-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00202878

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00202878, "IMPROVE-IT: Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin) vs Simvastatin (P04103)". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00202878. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*